新生儿门静脉血栓:危险因素、诊断、治疗建议及文献回顾
该研究回顾性评估23例新生儿门静脉血栓(PVT)的临床特征、危险因素、治疗及长期结局,并系统回顾11篇文献(共183例新生儿)。结果示87%为左门静脉血栓,91.3%至少有一个危险因素(脓毒症73.9%,脐静脉置管87%)。59.1%完全缓解,78.3%未接受抗凝治疗;34.8%有长期并发症。作者认为抗凝治疗对减少短期或长期并发症无证据,需设计良好的更大规模研究明确该问题。
要点
- 新生儿PVT最常见于左门静脉(87%),脐静脉置管(87%)与脓毒症(73.9%)是主要潜在危险因素。
- 23例中59.1%完全缓解,78.3%未接受抗凝治疗;部分缓解9例(40.9%),仅5例(21%)接受抗凝治疗。
- 抗凝组与非抗凝组部分或完全缓解平均持续时间分别为38.6天(8天至4个月)与12.6天(4天至3个月),作者认为抗凝治疗对PVT溶解的益处存疑。
- 长期并发症发生率为34.8%(8/23),平均随访7个月(1至12个月)。
- 作者建议在利弊关系中优先采用观察等待管理,并需设计良好的更大规模研究以制定适当的管理算法。
适用人群与场景
- 23例诊断为PVT的新生儿,其中11例早产儿、12例足月儿。
- 新生儿重症监护病房收治的患儿,PVT总体发生率为0.79/1000例新生儿重症监护入院,可能低估了真实PVT发生率。
处置流程与药物剂量
- 抗凝治疗组(ACT组)5例(21%)接受抗凝治疗;非抗凝组未接受抗凝治疗。
- 作者认为抗凝治疗对PVT溶解的益处存疑,在利弊关系中应优先采用观察等待管理。
研究设计与关键结果
- 回顾性评估23例(11例早产儿、12例足月儿)诊断为PVT的新生儿,诊断时中位年龄10天(范围3-90天),69.6%为女性。
- 87%为左门静脉血栓;91.3%至少有一个血栓危险因素,其中脓毒症占73.9%,脐静脉导管占87%。
- 59.1%的PVT在中位随访7个月(1个月至12个月)内完全缓解,其中78.3%未接受抗凝治疗;部分血栓缓解9例(40.9%)。
- 5例(21%)接受抗凝治疗;总体34.8%有长期并发症。
- 23例中部分或完全PVT缓解分别为9例(39%)和14例(61%),缓解时间平均18.4天(4天至4个月)。
- 早产儿与足月儿的部分缓解率和完全缓解率相似(40%和60% vs 37%和63%)。
- 抗凝组与非抗凝组部分或完全缓解平均持续时间分别为38.6天(8天至4个月)与12.6天(4天至3个月)。
- 系统回顾纳入11篇文献,共183例新生儿,其中102例未接受抗凝治疗,81例接受抗凝治疗;长期并发症率8/23(34%),平均随访7个月(1至12个月)。
证据类型、等级与局限
- 证据类型:回顾性研究(23例)及系统文献回顾(11篇文献,183例新生儿)。
- 局限:作者指出需设计良好的更大规模研究明确抗凝治疗对短期或长期并发症的影响,以制定适当的管理算法。
对床旁实践的改变
- 作者认为,新生儿PVT的抗凝治疗对减少短期或长期并发症无证据,在利弊关系中应优先采用观察等待管理。
- 作者建议需设计良好的更大规模研究以明确抗凝治疗的作用并制定适当的管理算法。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Neonatal portal vein thrombosis (PVT) is currently more commonly encountered as a result of advances in diagnostic tools and increase in invasive interventions.
METHODS: In this study, 11 premature and 12 term infants diagnosed with PVT were retrospectively evaluated for clinical and laboratory characteristics, umbilical catheterization procedure, PVT location, risk factors, treatments, and long-term outcomes.
RESULTS: Median age of the patients at diagnosis was 10 days (range 3-90 days), and 69.6% of patients were girls. Of the 23 patients, 87% had left PVT and, 91.3% had at least one thrombosis risk factor, which was sepsis in 73.9% of patients, and presence of umbilical venous catheter in 87%. Totally, 59.1% of PVTs were completely resolved in a median follow-up of 7 months (1 month to 12 months), and 78.3% of these patients had no anticoagulant therapy (ACT). Partial thrombus resolution was achieved in 9 patients (40.9%). Five patients (%21) received ACT. Overall, 34.8% of patients had long-term complications. neonatal PVT is most commonly reported in the left portal vein and there is no evidence for the impact of ACT on reducing the short- or long-term complications. Well designed and larger studies are necessary to clarify this issue, which can facilitate developing appropriate management algorithms.
CONCLUSION: Neonatal PVT is most commonly reported in the left portal vein and there is no evidence for the impact of ACT on reducing the short- or long-term complications. Well designed and larger studies are necessary to clarify this issue, which can facilitate developing appropriate management algorithms.
The overall incidence rate of PVT was 0,79/1000 neonatal intensive care admissions, possibly an underestimation of the incidence of true PVT. UVC insertion and sepsis were the leading potential risk factors for PVT.Among 23 infants, both of neonates showed partial or complete PVT resolution with 9(%39) and 14(%61) respectively, within 18,4 days (4 days to 4 months). In both premature and term neonates the PR and CR rates were similiar.(40% and 60% versus 37% and %63).In ACT recipients group (ACT group) and ACT non- recipients group(No ACT group), PR or CR mean duration were 38,6 days (8 days to 4 months) and 12,6 days (4 days to 3 months) respectively. This information may show us that the benefit of ACT therapy in the resolution of PVT is doubtful, and that wait-and-watch management should be prioritized in the profit-loss relationship.11 articles were included in the systematic review of literature. Total 183 neonates 102 were ACT untreated and 81 were ACT treated. Overall PR and CR are displayed on Table 4.Long-term complication rate was 8/23(%34) with mean 7 months(1 to 12 months) follow-up duration.
参考来源
- Solgun HA, Uysalol EP, Bayram C, et al. Neonatal portal vein thrombosis: risk factors, diagnosis, treatment recommendations and review of the literature. Thromb J. 2023. PMID: 37271816. doi:10.1186/s12959-023-00508-0
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。